Brokerages Set Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Target Price at $63.43

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has earned a consensus rating of “Moderate Buy” from the ten research firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and nine have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $63.4286.

A number of equities analysts have recently weighed in on DNTH shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Wednesday, October 8th. Guggenheim lifted their price target on shares of Dianthus Therapeutics from $92.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, September 9th. Truist Financial began coverage on shares of Dianthus Therapeutics in a research note on Tuesday, October 14th. They issued a “buy” rating and a $56.00 price target on the stock. Wedbush increased their price objective on shares of Dianthus Therapeutics from $44.00 to $46.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Finally, Raymond James Financial reissued an “outperform” rating and issued a $63.00 target price (up previously from $56.00) on shares of Dianthus Therapeutics in a research report on Tuesday, September 9th.

Insider Activity

In related news, EVP Simrat Randhawa sold 109,031 shares of the stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $38.14, for a total transaction of $4,158,442.34. Following the transaction, the executive vice president owned 4,000 shares of the company’s stock, valued at approximately $152,560. This represents a 96.46% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Ryan Savitz sold 20,000 shares of Dianthus Therapeutics stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $35.00, for a total value of $700,000.00. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 216,538 shares of company stock worth $8,079,575. 8.15% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Dianthus Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Fairmount Funds Management LLC grew its stake in shares of Dianthus Therapeutics by 22.2% in the third quarter. Fairmount Funds Management LLC now owns 3,307,191 shares of the company’s stock worth $130,138,000 after acquiring an additional 600,000 shares in the last quarter. Vestal Point Capital LP grew its stake in Dianthus Therapeutics by 88.2% during the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock worth $59,616,000 after purchasing an additional 1,499,931 shares in the last quarter. RA Capital Management L.P. increased its holdings in Dianthus Therapeutics by 53.6% during the 1st quarter. RA Capital Management L.P. now owns 2,866,733 shares of the company’s stock worth $52,003,000 after purchasing an additional 1,000,333 shares during the period. Wellington Management Group LLP raised its position in Dianthus Therapeutics by 3,366.9% in the 3rd quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock valued at $101,431,000 after purchasing an additional 2,503,311 shares in the last quarter. Finally, Octagon Capital Advisors LP boosted its stake in shares of Dianthus Therapeutics by 11.0% in the 1st quarter. Octagon Capital Advisors LP now owns 2,341,667 shares of the company’s stock valued at $42,478,000 after buying an additional 231,500 shares during the period. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Dianthus Therapeutics Price Performance

Dianthus Therapeutics stock opened at $40.79 on Monday. The firm has a 50 day simple moving average of $36.30 and a 200-day simple moving average of $26.05. The stock has a market cap of $1.75 billion, a price-to-earnings ratio of -11.72 and a beta of 1.56. Dianthus Therapeutics has a 1-year low of $13.36 and a 1-year high of $43.67.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.11). The business had revenue of $0.40 million during the quarter, compared to analyst estimates of $0.58 million. Dianthus Therapeutics had a negative net margin of 4,106.04% and a negative return on equity of 33.02%. Equities analysts expect that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.